|Mr. Sanj K. Patel||CEO & Chairman||1.43M||N/A||1970|
|Mr. Mark Ragosa C.F.A.||Sr. VP & CFO||N/A||N/A||1975|
|Mr. Michael R. Megna||Chief Accounting Officer & VP of Fin.||N/A||N/A||1971|
|Mr. Chad Morin||VP & Chief Compliance Officer||N/A||N/A||N/A|
|Ms. Madelyn Zeylikman||Gen. Counsel||N/A||N/A||N/A|
|Ms. Melissa Manno||Chief HR Officer||N/A||N/A||N/A|
|Dr. John F. Paolini||Sr. VP & Chief Medical Officer||N/A||N/A||1965|
|Mr. Rasmus Holm-Jorgensen||Sr. VP, Chief Strategy & Portfolio Officer||N/A||N/A||N/A|
|Mr. Carsten Boess||Exec. VP of Corp. Affairs||N/A||N/A||1967|
|Ms. Christine Maurer||Sr. VP of Program Management||N/A||N/A||N/A|
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 10; Compensation: 9.